Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

BACKGROUND: Amyloid-β 1–42 (Aβ(1–42)) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ(1–42) are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Schauer, Stephen P., Mylott, William R., Yuan, Moucun, Jenkins, Rand G., Rodney Mathews, W., Honigberg, Lee A., Wildsmith, Kristin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264029/
https://www.ncbi.nlm.nih.gov/pubmed/30486870
http://dx.doi.org/10.1186/s13195-018-0445-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264029/
https://www.ncbi.nlm.nih.gov/pubmed/30486870
http://dx.doi.org/10.1186/s13195-018-0445-0

Ejemplares similares